APGE
APOGEE THERAP (APGE)
NASDAQ
$132.84+$0.28 (+0.22%)
Price as of Jun 23, 2026 11:43 AM EDT
  • $8.2B
    Market Cap
  • 220.56%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
Income Statement
Total Operating Revenue
-30.0M
-13.56%
-34.7M
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
-30.0M
-13.56%
-34.7M
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-214.7M
+27.91%
-167.9M
+145.33%
-68.4M
N/A
Depreciation and Amortization Expense
1.4M
+650.26%
189,000
N/A
N/A
N/A
Total Operating Expenses
285.6M
+31.69%
216.9M
+133.19%
93.0M
N/A
Operating Profit
-285.6M
+31.69%
-216.9M
+133.19%
-93.0M
N/A
Interest Income
30.0M
-13.56%
34.7M
+285.25%
9.0M
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
30.0M
-13.56%
34.7M
+285.25%
9.0M
N/A
Total Nonoperating Income and Expense
30.0M
-13.56%
34.7M
+285.25%
9.0M
N/A
Income before Taxes
-255.6M
+40.32%
-182.1M
+95.83%
-93.0M
N/A
Income Taxes
278,000
+1,444.44%
18,000
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-255.8M
+40.46%
-182.1M
+116.88%
-84.0M
N/A
Net Income from Continuing Operations Applicable to Common
-255.6M
+40.32%
-182.1M
+116.86%
-84.0M
N/A
Basic EPS and Net Income
-4.22
+27.88%
-3.30
-1.79%
-3.36
N/A
Diluted EPS and Net Income
-4.22
+27.88%
-3.30
-1.79%
-3.36
N/A
Basic Weighted Average Shares
60.7M
+9.96%
55.2M
+120.72%
25.0M
N/A
Diluted Weighted Average Shares
60.7M
+9.96%
55.2M
+120.72%
25.0M
N/A
Balance Sheet
Cash and Cash Equivalents
131.5M
-7.22%
141.8M
+19.84%
118.3M
N/A
Short-Term Investments
598.6M
+58.01%
378.9M
+36.70%
277.1M
N/A
Cash and Cash Equivalents and Short-Term Investments
730.2M
+40.25%
520.7M
+31.66%
395.5M
N/A
Total Current Assets
741.4M
+39.95%
529.7M
+32.96%
398.4M
N/A
Accumulated Depreciation
1.6M
+750.79%
189,000
N/A
N/A
N/A
Property and Plant and Equipment and Net
5.7M
+190.35%
2.0M
+419.63%
377,000
N/A
Total Long-Term Assets
8.7M
+1,641.16%
498,000
+24.19%
401,000
N/A
Total Assets
937.1M
+24.30%
754.0M
+87.83%
401.4M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
27.9M
-2.29%
28.6M
+38.92%
20.6M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
5.3M
-37.83%
8.6M
+821.44%
933,000
N/A
Total Liabilities
33.3M
-10.51%
37.2M
+72.90%
21.5M
N/A
Retained Earnings
-561.8M
+83.63%
-305.9M
+147.16%
-123.8M
N/A
Total Stockholders Equity
903.9M
+26.10%
716.8M
+88.67%
379.9M
N/A
Total Shares Outstanding
68.4M
+17.81%
58.1M
+20.12%
48.3M
N/A
Cash Flow
Cash from Operating Activities
-227.4M
+32.88%
-171.2M
+128.96%
-74.8M
N/A
Capital Expenditures
5.1M
+346.79%
1.2M
+589.82%
167,000
N/A
Cash from Investing Activities
-179.6M
-40.23%
-300.5M
+9.69%
-273.9M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
396.5M
-19.92%
495.1M
+56.98%
315.4M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
951.03%
+52.35%
624.23%
N/A
N/A
N/A
Return on Assets
-30.26%
-4.04%
-31.53%
N/A
N/A
N/A
Return on Equity
-31.57%
-4.95%
-33.22%
N/A
N/A
N/A
Revenue Growth
13.56%
N/A
N/A
N/A
N/A
N/A
Current Ratio
26.57
+43.23%
18.55
N/A
N/A
N/A
Cash Ratio
4.71
-5.05%
4.96
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow